Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – Time to Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares gapped up prior to trading on Tuesday . The stock had previously closed at $17.40, but opened at $17.87. Pulse Biosciences shares last traded at $18.04, with a volume of 23,965 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Tuesday.

Pulse Biosciences Price Performance

The stock has a fifty day moving average price of $17.97 and a 200 day moving average price of $16.70.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the prior year, the firm earned ($0.19) earnings per share.

Insider Activity

In other news, Director Robert W. Duggan acquired 56,054 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the transaction, the director now owns 42,228,057 shares of the company’s stock, valued at $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently made changes to their positions in PLSE. Quest Partners LLC purchased a new position in Pulse Biosciences in the 2nd quarter worth $91,000. Creative Planning increased its holdings in shares of Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares during the period. Franklin Resources Inc. bought a new stake in shares of Pulse Biosciences in the 3rd quarter valued at about $378,000. Rhumbline Advisers boosted its holdings in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the period. Finally, Barclays PLC grew its position in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after acquiring an additional 23,738 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.